Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Panmure Liberum starts coverage of DFS at 'buy' with 300p price target

(Sharecast News) - Panmure Liberum initiated coverage of furniture retailer DFS on Thursday with a 'buy' rating and 300p price target. It said DFS's business can be characterised as one of leading market share, entrenched economic moats, significant barriers to entry and high brand awareness.

"The group has gone through a transformation the last three years and is now at an inflection on monetising these attributes," it said.

"The shares do not reflect the changes in the model, the superior earnings profile on offer and future value creation."

Panmure said DFS's 36% market share provides profound network effects, adding that the company's name is searched 1.8x more online than the term 'sofa'.

It pointed out that DFS spends £120m a year on interest-free credit, making it very hard for any other company to attack this share.

"Add to this exclusive brand partnerships elevating the offer and the fact that NPS is more than 92% due to its vertically integrated delivery model. We are not surprised it is 3x the size of its nearest competitor, taking share."

Panmure said that against the lacklustre macro backdrop, DFS's order book is double-digit and revenues are back in growth.

"Consumer confidence is the main driver of big-ticket items and with consumer balance sheets in a good place, lower interest rates could be the unlocking mechanism here," it said.

"DFS has enhanced its business model and any recovery in revenues should drop through at 20% to 25%."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.